Hepatitis B and hepatocellular carcinoma recurrence after living donor liver transplantation: The role of the Milan criteria

Vatansever, Sezgin; Farajov, Rasim; Yılmaz, Hüseyin; Zeytunlu, Murat; Paköz, Zehra Betül; Kılıç, Murat

doi:10.5152/tjg.2018.18794

Cited by 4 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[30] However, several studies have shown a close association between HBV infection and HCC recurrence. [35][36][37] In our study, HBV infection in donors and recipients did not in uence HCC recurrence with concurrent use of HBIG and NA.…”

Section: Discussionmentioning

confidence: 86%

Safe Use of Hepatitis B Surface Antigen-Positive Grafts in Liver Transplantation: A Nationwide Study Based on the KOTRY Data

Gang

Choi

Lee

et al. 2023

Preprint

View full text Add to dashboard Cite

In the era of nucleoside analogs (NA), we investigated liver transplantation (LT) outcomes using hepatitis B surface antigen (HBsAg)-positive(+) grafts and Korean Organ Transplantation Registry (KOTRY) data. The KOTRY database registered 4,265 LTs between April 2014 and January 2020; 20 (0.5%) using HBsAg(+) grafts were identified. HBsAg(+) liver grafts [S(+)] were compared to HBsAg-negative(−) liver grafts (n = 4,100) for LT outcomes. The S(+) group was compared with LTs using HBsAg(−)/hepatitis B core antibody (HBcAb) (+) [C(+), n = 882] and HBsAg(−)/HBcAb(−) [SC(−), n = 3,132] grafts by propensity score matching (PSM) (1:1). Sixteen of 20 HBsAg(+) graft recipients maintained hepatitis B immunoglobulin. Tenofovir is the most commonly used NA. Compared to the HBsAg(II) group, the S(+) group showed no significant differences in patient (P = 0.332) or graft survival (P = 0.152). Age (hazard ratio [HR] = 1.03, P = 0.016), hepatocellular carcinoma (HCC) (HR = 4.61, P < 0.001), the model for end-stage liver disease (MELD) score (HR = 2.82, P = 0.001), ascites (HR = 2.14, P = 0.002), and encephalopathy (HR = 2.53, P < 0.001) were risk factors for patient survival. The graft survival risk factors were HCC (HR = 4.01, P = 0.001), preoperative treatment for HCC (HR = 0.54, P = 0.006), MELD score (HR = 2.14, P = 0.012), ascites (HR = 2.52, P < 0.001), and encephalopathy (HR = 1.99, P < 0.001). PSM between groups S(+) and C(+) and groups S(+) and SC(−) revealed no significant difference in patient survival (P = 0.863 and P = 0.547, respectively) or graft survival (P = 0.576 and P = 0.327, respectively). In hepatitis B virus (HBV)-endemic areas, HBsAg(+) liver grafts can expand the donor pool without compromising outcomes.

show abstract

Section: Discussionmentioning

confidence: 86%

Safe Use of Hepatitis B Surface Antigen-Positive Grafts in Liver Transplantation: A Nationwide Study Based on the KOTRY Data

Gang

Choi

Lee

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Especially in case 11, HCC recurrence was suspected at the time of HBV recurrence based on previous reports and our own experience, and resection for lung metastasis could be performed at an early stage ( Figure 2D). Vatansever et al reported that the HBV and HCC recurrence are closely related in patients who underwent LT due to HBV-associated HCC (24). They also insisted that the HBV recurrence after LT increases the risk of HCC recurrence.…”

Section: Discussionmentioning

confidence: 99%

Risk factors for hepatitis B virus recurrence after living donor liver transplantation: A 22-year experience at a single center

Bae

Akamatsu

Ichida

et al. 2020

BST

View full text Add to dashboard Cite

systemic chemotherapy (9), and pre-LT HCC and post-LT HCC recurrence (10-13). The aim of the present study was to assess the incidence and risk factors associated with HBV recurrence in living donor liver transplantation (LDLT) recipients over a 20-year period. We analyzed a retrospective series of patients who underwent LDLT for HBV-related liver disease, and evaluated their virologic and biochemical data, tumor burden, antiviral therapy, and immunosuppressive therapy. 2. Methods 2.1. Patients

show abstract

Pathologic response translates to improved patient survival after locoregional treatment for hepatocellular carcinoma: the importance of minimally invasive microwave ablation

Baimas-George

Watson

et al. 2020

Surg Endosc

View full text Add to dashboard Cite

Hepatitis B and hepatocellular carcinoma recurrence after living donor liver transplantation: The role of the Milan criteria

Cited by 4 publications

References 23 publications

Safe Use of Hepatitis B Surface Antigen-Positive Grafts in Liver Transplantation: A Nationwide Study Based on the KOTRY Data

Safe Use of Hepatitis B Surface Antigen-Positive Grafts in Liver Transplantation: A Nationwide Study Based on the KOTRY Data

Risk factors for hepatitis B virus recurrence after living donor liver transplantation: A 22-year experience at a single center

Pathologic response translates to improved patient survival after locoregional treatment for hepatocellular carcinoma: the importance of minimally invasive microwave ablation

Contact Info

Product

Resources

About